Power Law company profile

Cytodyn

Biotech & Life Sciences · Lake Oswego, United States · Founded 2002 · IPO 2005 Unicorn

Biotechnology company focused on the development of new therapies to combat infections with immune deficiency viruses

Valuation

$435M

Market cap · May/2026

EBITDA

$9.0M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Global footprint

Where Cytodyn has talent and traffic

Workforce by country

1 countries with
team presence

🇺🇸 United States100%

1 country shown

Web traffic by country

5.3K monthly visits
across markets

🇺🇸 United States100%

Top 1 markets shown

Patent intelligence

$40M patent portfolio · 31 active families

Estimated portfolio value

$40M

9.3% of market cap · 6.8× smaller than top peer argenx ($275M)

31 active patent families

Where Cytodyn innovates Molecular biologyCD4 antigenChemokine receptor CCR5HIV receptorMethylnaltrexone

Where Cytodyn concentrates vs peers

Each axis is a top-10 topic across Cytodyn and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Cytodyn

An AI-synthesized read of the highest-engagement posts about Cytodyn on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Cytodyn on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles